Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 61 |
| Active Pipeline (Recruiting Now) | 22 (11) |
| Completed vs Stopped Early | 19 / 20 (32.8%) |
| Median Closed Actual Enrollment | 155 participants |
| Physical Hospital Site Disclosure | 84.6% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 12 (6 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| UCLA Health and Jonsson Comprehensive Cancer Center | Los Angeles, CA | 15 |
| University of Colorado Anschutz Medical Campus | Aurora, CO | 14 |
| Cleveland Clinic | Cleveland, OH | 13 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07219043 | A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammat | Phase II | RECRUITING |
| NCT06962800 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) | Phase III | RECRUITING |
| NCT06935357 | A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | Phase III | RECRUITING |
| NCT04895241 | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have S | Phase III | ACTIVE NOT RECRUITING |
| NCT06685757 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rej | Phase III | ACTIVE NOT RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Biogen Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.